https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-fr/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-fr/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-ja/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-ja/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-vi/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-pt/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-ja/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-es/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-ar/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-pt/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-ru/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-id/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-es/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-th/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-vi/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-ms/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-ar/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-ru/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-id/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-th/ 2026-07-11T06:35:18+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-zh-tw/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-ms/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-fr/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-de/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-zh-tw/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-ja/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-fr/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-pt/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-de/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-es/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-ja/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-pt/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-es/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-ar/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-ru/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-id/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-th/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-vi/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma-the-new-england-journal-of-medicine-ms/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive/ 2026-07-11T06:35:17+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-de/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-ja/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-pt/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-es/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-ar/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-ru/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-ar/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-id/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-ru/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-th/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-id/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-th/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-vi/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma-onclive-ms/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/long-term-partial-response-in-a-patient-with-liver-metastasis-of-primary-adrenocortical-carcinoma-with-adjuvant-mitotane-plus-transcatheter-arterial-chemoembolization-and-microwave-ablation-a-case-re/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-zh-tw/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-fr/ 2026-07-11T06:35:16+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-es/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-ar/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-ru/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-id/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-th/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-vi/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-ms/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-vi/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-zh-tw/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/managing-post-transplant-relapse-in-flt3-mutated-aml-with-gilteritinib-rzetelska-acta-haematologica-polonica-via-medica-journals-ms/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-fr/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-de/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-zh-tw/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-ja/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-fr/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-pt/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-de/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-es/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-ja/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/efficacy-of-gilteritinib-in-comparison-with-alectinib-for-the-treatment-of-alk-rearranged-non-small-cell-lung-cancer-wiley-online-library-pt/ 2026-07-11T06:35:15+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-id/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-ms/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-th/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-vi/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-ms/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-zh-tw/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-fr/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-de/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-ja/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-pt/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-es/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-ar/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-ru/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-id/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-ar/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-th/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/gilteritinib-maintenance-therapy-after-transplantation-in-patients-with-flt3-itd-aml-who-have-measurable-residual-disease-the-asco-post-ru/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll-pr-newswire-vi/ 2026-07-11T06:35:14+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-fr/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-de/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-zh/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-ja/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-fr/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-pt/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-de/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-es/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-ja/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-ar/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-pt/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-es/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-ar/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-ru/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-id/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-th/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-vi/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/cpx-351-liposomal-cytarabine-and-daunorubicin-versus-venetoclax-plus-hypomethylating-agent-therapy-in-newly-diagnosed-acute-myeloid-leukemia-a-retrospective-comparison-involving-600-mayo-clinic-pat-ms/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-zh-tw/ 2026-07-11T06:35:13+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-pt/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-es/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-ar/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-ru/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-id/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-th/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-ru/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-vi/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-id/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-ms/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-th/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-vi/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-zh-tw/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-calquence-acalabrutinib-date-of-authorisation-05-11-2020-revision-12-status-authorised-ms/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-zh-tw/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-fr/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-de/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/new-benchmark-for-targeted-therapies-in-lung-cancer-median-progression-free-survival-for-lorlatinib-in-advanced-alk-non-small-cell-lung-cancer-surpasses-5-years-asco-publications-ja/ 2026-07-11T06:35:12+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-ru/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-id/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-th/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-vi/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-ms/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-zh-tw/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-fr/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-de/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-ja/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-fr/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-pt/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-de/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-es/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-ja/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-ar/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-pt/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-ru/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-es/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/efficacy-and-safety-of-first-line-acalabrutinib-plus-venetoclax-revamps-qol-outcomes-in-cll-onclive-ar/ 2026-07-11T06:35:11+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-vi/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-ms/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-zh-tw/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-fr/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-de/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-ja/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-pt/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-es/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-ar/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-ru/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-id/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-th/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-vi/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-id/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/from-discovery-to-clinical-impact-aacr-special-conference-captured-the-spectrum-of-lymphoma-research-ms/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/development-and-validation-of-a-liquid-chromatography-coupled-to-a-diode-array-detector-lc-dad-method-for-measuring-mitotane-ddd-in-plasma-samples-elsevier-th/ 2026-07-11T06:35:10+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-zh-tw/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-ja/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-fr/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-pt/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-de/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-ja/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-pt/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-es/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-ar/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-ru/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-id/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-th/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-vi/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026-ms/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-zh-tw/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-fr/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/fda-approvals-in-oncology-april-june-2026/ 2026-07-11T06:35:09+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-de/ 2026-07-11T06:35:09+00:00